Sars Recombinant Spike Protein
Lab Reagents
Human IgG antibody Laboratories manufactures the sars recombinant spike protein reagents distributed by Genprice. The Sars Recombinant Spike Protein reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Recombinant. Other Sars products are available in stock. Specificity: Sars Category: Recombinant Group: Spike Protein
Recombinant Coronavirus Spike Protein (SARS-CoV S2) |
|||
P1519-10 | Biovision | 10µg | EUR 156 |
Recombinant Coronavirus Spike Protein (SARS-CoV S2) |
|||
P1519-50 | Biovision | 50µg | EUR 551 |
SARS Coronavirus spike (HSZ-Cc) Recombinant Protein |
|||
20-219 | ProSci | 0.1 mg | EUR 605.75 |
Description: SARS Coronavirus spike (HSZ-Cc) Recombinant Protein |
SARS Coronavirus Spike Mosaic Recombinant protein (Center) |
|||
39-122 | ProSci | 0.1 mg | EUR 464 |
Description: SARS Coronavirus is an enveloped virus containing three outer structural proteins, namely the membrane (M), envelope (E), and spike (S) proteins. Spike (S)-glycoprotein of the virus interacts with a cellular receptor and mediates membrane fusion to allow viral entry into susceptible target cells. Accordingly, S-protein plays an important role in virus infection cycle and is the primary target of neutralizing antibodies. |
SARS-CoV Spike Antibody |
|||
3219-002mg | ProSci | 0.02 mg | EUR 171.82 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3219-01mg | ProSci | 0.1 mg | EUR 436.42 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3221-002mg | ProSci | 0.02 mg | EUR 171.82 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3221-01mg | ProSci | 0.1 mg | EUR 436.42 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3223-002mg | ProSci | 0.02 mg | EUR 171.82 |
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3223-01mg | ProSci | 0.1 mg | EUR 436.42 |
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3225-002mg | ProSci | 0.02 mg | EUR 171.82 |
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3225-01mg | ProSci | 0.1 mg | EUR 436.42 |
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS (IN1) Spike Peptide |
|||
3221P | ProSci | 0.05 mg | EUR 164.75 |
Description: (IN) SARS (IN1) Spike peptide |
SARS (IN2) Spike Peptide |
|||
3223P | ProSci | 0.05 mg | EUR 164.75 |
Description: (IN) SARS (IN2) Spike peptide |
SARS (IN3) Spike Peptide |
|||
3225P | ProSci | 0.05 mg | EUR 164.75 |
Description: (IN) SARS (IN3) Spike peptide |
Recombinant SARS Coronavirus Spike, GST-Tagged |
|||
DAG534 | Creative Diagnostics | 1mg | EUR 1556 |
Recombinant SARS-CoV Spike protein [GST] (37 kDa) |
|||
VAng-Wyb8620-inquire | Creative Biolabs | inquire | Ask for price |
Description: SARS-CoV C-terminal of the Spike protein (37 kDa), recombinant protein from E. coli, 1 mg/mL. |